Natco Pharma Ltd.

NSE: NATCOPHARM | BSE: 524816

Mid-range Performer

Download real time

867.50 -25.30 (-2.83%)

42.36% Fall from 52W High

698.3K NSE+BSE Volume

NSE 10 Dec, 2025 3:31 PM (IST)

15,537.8

Market Cap

High in industry

-

Beta 1Year

Very High Volatility

Natco Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for NATCOPHARM, BSE:524816 Natco Pharma Ltd.

Search Inside the pdf :

Natco Pharma Ltd.

15 Nov 2025

867.50

-2.83%

Earnings hiccups imminent

buy

Sell: Natco Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Natco’s Q2FY26 result was ahead of our expectations, driven by higher supplies of gRevlimid which would fade away in H2FY26; management guides for profitability to drop to INR 2.75-3bn in H2 (vs. INR 10bn in H1).

Natco Pharma has lost -41.62% in the last 1 Year

Natco Pharma Ltd.

17 Sep 2025

867.50

-2.83%

NATCO PHARMA

buy

Hold: Natco Pharma Ltd.

Target

Geojit BNP Paribas

The management maintains a long-term perspective on the business, aiming to navigate potential challenges and seize growth opportunities. We anticipate a steep revenue degrowth because of lower Revlimid sales in FY27. Focus will shift on the domestic formulations business with the anticipated launches of Semaglutide, which strengthens our case for...

Number of MF schemes decreased from 47 to 19 in Sep 2025 qtr

Natco Pharma Ltd.

11 Jun 2025, 12:00AM

867.50

-2.83%

NATCO PHARMA

buy

Hold: Natco Pharma Ltd.

Target

Geojit BNP Paribas

The company unveiled its R&D product NRC-2694 for metastatic head and neck cancer, which is currently in phase 2. The management expects to gain more clarity after a year and a half. The company currently is doing patient recruitment...

Natco Pharma Ltd. is trading below its 100 day SMA of 871.4

Natco Pharma Ltd.

30 May 2025

867.50

-2.83%

Near-term outlook bleak; pipeline build-up underway

buy

Hold: Natco Pharma Ltd.

Target

ICICI Securities Limited

Natco’s Q4FY25 result was driven by better traction in gRevlimid and the momentum is likely to continue for next couple of quarters.

Number of FII/FPI investors decreased from 317 to 235 in Sep 2025 qtr

Natco Pharma Ltd.

19 Mar 2025

867.50

-2.83%

NATCO PHARMA

buy

Hold: Natco Pharma Ltd.

Target

Geojit BNP Paribas

Number of MF schemes decreased from 47 to 19 in Sep 2025 qtr

Natco Pharma Ltd.

07 Oct 2024

867.50

-2.83%

Natco Pharma

buy

Buy: Natco Pharma Ltd.

Target

ICICI Direct

Natco Pharma Ltd. is trading below its 100 day SMA of 871.4

Natco Pharma Ltd.

04 Oct 2024

867.50

-2.83%

FundsIndia

Natco Pharma Ltd. has an average target of 845.00 from 2 brokers.

Natco Pharma Ltd.

20 Aug 2024

867.50

-2.83%

NATCO PHARMA

buy

Accumulate: Natco Pharma Ltd.

Target

Geojit BNP Paribas

Natco Pharma has lost -41.62% in the last 1 Year

Natco Pharma Ltd.

13 Aug 2024

867.50

-2.83%

Setting the stage for a strong FY25

buy

Hold: Natco Pharma Ltd.

Target

ICICI Securities Limited

Natco’s Q1FY25 beat was driven by higher sales of gRevlimid while its subsidiaries in Brazil and Canada (INR 1.8bn of sales) also did well.

Natco Pharma Ltd. is trading below its 100 day SMA of 871.4

Natco Pharma Ltd.

30 May 2024

867.50

-2.83%

Natco Pharma

buy

Buy: Natco Pharma Ltd.

Recommendation Target

ICICI Direct

Number of FII/FPI investors decreased from 317 to 235 in Sep 2025 qtr

Is Natco Pharma Ltd. worth buying?

594 Votes:

Buy 83.0%

Sell 7.41%

Hold 9.6%

RESEARCH REPORTS

Sell SEE REPORTS >

Hold SEE REPORTS >